Insulin-like growth factor receptor I (IGF-IR) and vascular endothelial growth factor receptor 2 (VEGFR-2) are expressed on the circulating epithelial tumor cells of breast cancer patients.

<h4>Background</h4>Circulating epithelial tumor cell (CETC) analysis is a promising diagnostic field for estimating the risk for metastatic relapse and progression in patients with malignant disease. CETCs characterization can be used as a liquid biopsy for prognostic and predictive purp...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Monika Pizon, Dorothea Sonja Zimon, Ulrich Pachmann, Katharina Pachmann
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/b34fd3cff9c749819feee132af9668a2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b34fd3cff9c749819feee132af9668a2
record_format	dspace
spelling	oai:doaj.org-article:b34fd3cff9c749819feee132af9668a22021-11-18T07:57:34ZInsulin-like growth factor receptor I (IGF-IR) and vascular endothelial growth factor receptor 2 (VEGFR-2) are expressed on the circulating epithelial tumor cells of breast cancer patients.1932-620310.1371/journal.pone.0056836https://doaj.org/article/b34fd3cff9c749819feee132af9668a22013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23418605/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Circulating epithelial tumor cell (CETC) analysis is a promising diagnostic field for estimating the risk for metastatic relapse and progression in patients with malignant disease. CETCs characterization can be used as a liquid biopsy for prognostic and predictive purposes in breast and other cancers. IGF-IR and VEGFR-2 play an important role in tumor growth and the progression of cancer disease. The purpose of the current study was therefore to investigate their expression on CETCs.<h4>Methods</h4>CETCs were determined from the blood of 50 patients suffering from breast cancer. The number of vital CETCs and the expression of IGF-IR and VEGFR-2 were investigated using the maintrac® method.<h4>Results</h4>IGF-IR and VEGFR-2 expression on the surface of CETCs were detected in 84% of patients. A statistically high correlation was found between IGF-IR and VEGFR-2 (r = 0.745 and p<0.001) on the CETCs. The co-expression of both receptors was confirmed in some experiments and ranged between 70% and 100%. Statistically significant correlations were observed between the number of CETCs and IGF-IR (r = 0.315 and p<0.05) and VEGFR-2 (r = 0.310 and p<0.05) expression. The presence of CETCs and the level of IGF-IR and VEGFR-2 expression were not associated with tumor stage, hormone receptor status or nodal/distant metastasis.<h4>Summary</h4>In this study, a parallel and co-expression of IGF-IR and VEGFR-2 was examined on the surface of CETCs in breast cancer patients for the first time. Characterization of CETCs may be a promising approach for the rational design of targeted anticancer therapies.Monika PizonDorothea Sonja ZimonUlrich PachmannKatharina PachmannPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 2, p e56836 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Monika Pizon Dorothea Sonja Zimon Ulrich Pachmann Katharina Pachmann Insulin-like growth factor receptor I (IGF-IR) and vascular endothelial growth factor receptor 2 (VEGFR-2) are expressed on the circulating epithelial tumor cells of breast cancer patients.
description	<h4>Background</h4>Circulating epithelial tumor cell (CETC) analysis is a promising diagnostic field for estimating the risk for metastatic relapse and progression in patients with malignant disease. CETCs characterization can be used as a liquid biopsy for prognostic and predictive purposes in breast and other cancers. IGF-IR and VEGFR-2 play an important role in tumor growth and the progression of cancer disease. The purpose of the current study was therefore to investigate their expression on CETCs.<h4>Methods</h4>CETCs were determined from the blood of 50 patients suffering from breast cancer. The number of vital CETCs and the expression of IGF-IR and VEGFR-2 were investigated using the maintrac® method.<h4>Results</h4>IGF-IR and VEGFR-2 expression on the surface of CETCs were detected in 84% of patients. A statistically high correlation was found between IGF-IR and VEGFR-2 (r = 0.745 and p<0.001) on the CETCs. The co-expression of both receptors was confirmed in some experiments and ranged between 70% and 100%. Statistically significant correlations were observed between the number of CETCs and IGF-IR (r = 0.315 and p<0.05) and VEGFR-2 (r = 0.310 and p<0.05) expression. The presence of CETCs and the level of IGF-IR and VEGFR-2 expression were not associated with tumor stage, hormone receptor status or nodal/distant metastasis.<h4>Summary</h4>In this study, a parallel and co-expression of IGF-IR and VEGFR-2 was examined on the surface of CETCs in breast cancer patients for the first time. Characterization of CETCs may be a promising approach for the rational design of targeted anticancer therapies.
format	article
author	Monika Pizon Dorothea Sonja Zimon Ulrich Pachmann Katharina Pachmann
author_facet	Monika Pizon Dorothea Sonja Zimon Ulrich Pachmann Katharina Pachmann
author_sort	Monika Pizon
title	Insulin-like growth factor receptor I (IGF-IR) and vascular endothelial growth factor receptor 2 (VEGFR-2) are expressed on the circulating epithelial tumor cells of breast cancer patients.
title_short	Insulin-like growth factor receptor I (IGF-IR) and vascular endothelial growth factor receptor 2 (VEGFR-2) are expressed on the circulating epithelial tumor cells of breast cancer patients.
title_full	Insulin-like growth factor receptor I (IGF-IR) and vascular endothelial growth factor receptor 2 (VEGFR-2) are expressed on the circulating epithelial tumor cells of breast cancer patients.
title_fullStr	Insulin-like growth factor receptor I (IGF-IR) and vascular endothelial growth factor receptor 2 (VEGFR-2) are expressed on the circulating epithelial tumor cells of breast cancer patients.
title_full_unstemmed	Insulin-like growth factor receptor I (IGF-IR) and vascular endothelial growth factor receptor 2 (VEGFR-2) are expressed on the circulating epithelial tumor cells of breast cancer patients.
title_sort	insulin-like growth factor receptor i (igf-ir) and vascular endothelial growth factor receptor 2 (vegfr-2) are expressed on the circulating epithelial tumor cells of breast cancer patients.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/b34fd3cff9c749819feee132af9668a2
work_keys_str_mv	AT monikapizon insulinlikegrowthfactorreceptoriigfirandvascularendothelialgrowthfactorreceptor2vegfr2areexpressedonthecirculatingepithelialtumorcellsofbreastcancerpatients AT dorotheasonjazimon insulinlikegrowthfactorreceptoriigfirandvascularendothelialgrowthfactorreceptor2vegfr2areexpressedonthecirculatingepithelialtumorcellsofbreastcancerpatients AT ulrichpachmann insulinlikegrowthfactorreceptoriigfirandvascularendothelialgrowthfactorreceptor2vegfr2areexpressedonthecirculatingepithelialtumorcellsofbreastcancerpatients AT katharinapachmann insulinlikegrowthfactorreceptoriigfirandvascularendothelialgrowthfactorreceptor2vegfr2areexpressedonthecirculatingepithelialtumorcellsofbreastcancerpatients
_version_	1718422751429001216

Insulin-like growth factor receptor I (IGF-IR) and vascular endothelial growth factor receptor 2 (VEGFR-2) are expressed on the circulating epithelial tumor cells of breast cancer patients.

Ejemplares similares